Eli Lilly breaks ground on $3.5 billion Pennsylvania obesity drug plant
PR Newswire · · AI-summarised by FinFlash
Eli Lilly began construction of a $3.5 billion manufacturing site in Fogelsville, in Pennsylvania's Lehigh Valley, to make next-generation obesity injectables including the investigational triple agonist retatrutide. The plant, expected to operate by 2031, will create about 850 permanent jobs and roughly 2,000 construction roles. It is Lilly's tenth new US site since 2020 and part of a $50 billion domestic production push as demand for weight-loss drugs keeps rising.
So What?
Reinforces Lilly's long-term capacity lead in obesity drugs and its onshoring story amid US tariff pressure on pharma. Watch for retatrutide regulatory milestones that this capacity is built to serve.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.